Targeting mTOR Shows Promise in Cutaneous Sarcoidosis
Vienna researchers reported that 7 of 10 patients treated with systemic sirolimus had noted improvements in skin lesions, which continued for up to 2 years of follow-up.
Stay updated with breaking news from Georg Stary. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Vienna researchers reported that 7 of 10 patients treated with systemic sirolimus had noted improvements in skin lesions, which continued for up to 2 years of follow-up.
A research team led by Georg Stary (Medical University of Vienna and CeMM) has identified a new approach to treating the inflammatory disease sarcoidosis.
Researchers in Vienna, including from the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases have discovered processes that can contribute to the success of stem cell transplantation, for example in the treatment of leukaemia. Click to read more...
Skin microbiome research could lead to new approaches for addressing organ damage after stem cell transplants
Organ damage occurs in up to 70 percent of patients in the first few months following stem cell transplant. The precise reasons for this potentially life-threatening reaction have long been the subject of scientific research.